Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Amkay Products IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds
Profile
Issue Size --
Profile
Price Range 52  to  55 per share
Profile
Min Investment ₹55
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Amkay Products Ltd is a dynamic company specializing in the manufacturing and distribution of a diverse range of healthcare and hygiene products. Established with a commitment to quality and innovation, Amkay offers an extensive portfolio including disposable medical supplies, surgical instruments, personal protective equipment (PPE), and sanitation solutions. With a focus on meeting the evolving needs of the healthcare industry, the company leverages cutting-edge technology and stringent quality control measures to ensure the efficacy and reliability of its products. Amkay Products Ltd operates with a customer-centric approach, prioritizing customer satisfaction and safety. Through continuous research and development, Amkay strives to enhance healthcare practices and improve public health outcomes globally. Read More

Basic Info

Face Value 10 per share

Price 52  to  55 per share

P/E (x) 13.8

Sales( Cr.) 38

PAT( Cr.) 3

EPS 4

Draft Prospectus --

Exchange BSE-SME

Promoter

Company Promoters

Kashyap Pravin Mody Himanshu Kantilal Batavia.

Pre Issue Share Holding 100%

Post Issue Share Holding 70.52%

Listing Details:

Listing Price: 104.5

Listing Gain: 47.37%

Current Price: 57

Gain On Issue: 57 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Apr 30, 2024
Closing Date May 03, 2024
Allotment May 06, 2024
Refund May 07, 2024
Delivery of Shares May 07, 2024
Listing Date May 08, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2000 110,000
Retail (Max) 1 2000 110,000
S-HNI (Min) 2 4000 220,000
S-HNI (Max) 9 18000 990,000
B-HNI (Min) 10 20000 1,100,000

Objective of the Issue

1. Funding Capital Expenditure towards the installation of additional Machinery 2. To meet working capital requirements 3. General Corporate Purpose.

Issue

Category Nos Bid Bid (x)
QIB 1146000 198303840 173x
NII 343800 339447492 987.3x
Retail 802200 780652908 973.1x
EMP 0 0 0x
Total 2292000 1714484760 748x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Amkay Products Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 41 37 28 31 38
Other Income 0 0 0 1 1
Total Income 41 37 28 32 40
Total Expenditure 36 34 25 28 34
Operating Profit 5 3 4 5 5
Interest 0 0 0 1 0
Depreciation 0 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0
Profit Before Tax 4 2 2 4 4
Provision for Tax 1 1 1 1 1
Profit After Tax 3 1 2 3 3
Adjustments 0 0 0 0 0
Profit After Adjustments 3 1 2 3 3
Adjusted Earnings Per Share 4.9 2.3 2.4 4.1 3.9

Amkay Products Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 5 6 8 10 24
Minority's Interest 0 0 0 0 0
Borrowings 1 3 3 1 1
Other Non-Current Liabilities -0 -0 0 -0 -0
Total Current Liabilities 8 6 5 7 5
Total Liabilities 14 16 16 18 30
Fixed Assets 2 4 3 3 4
Other Non-Current Assets 1 2 4 4 8
Total Current Assets 10 10 9 11 17
Total Assets 14 16 16 18 30

Amkay Products Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 1 0 0 0
Cash Flow from Operating Activities 3 -0 1 -1 -0
Cash Flow from Investing Activities -2 -3 -1 0 -6
Cash Flow from Financing Activities -1 3 0 0 8
Net Cash Inflow / Outflow 1 -1 -0 0 1
Closing Cash & Cash Equivalent 1 0 0 0 2

Amkay Products Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 4.91 2.31 2.41 4.13 3.86
CEPS(Rs) 5.36 3.15 3.53 5.01 4.82
DPS(Rs) 0 0 0 0 0
Book NAV/Share(Rs) 7.45 9.75 12.16 15.72 27.8
Core EBITDA Margin(%) 11.28 7.36 11.36 10.72 10.75
EBIT Margin(%) 10.79 6.69 10.2 12.95 12.02
Pre Tax Margin(%) 10.26 5.58 8.41 11.27 11.19
PAT Margin (%) 7.68 4.02 5.51 8.47 8.7
Cash Profit Margin (%) 8.38 5.49 8.05 10.25 10.86
ROA(%) 22.92 10.05 9.84 15.76 14.1
ROE(%) 65.98 26.81 22 29.65 19.6
ROCE(%) 71.91 29.32 24.73 28.84 21.89
Receivable days 36.68 38.62 48.07 45.19 47.54
Inventory Days 2.58 11.36 30.08 48.3 65.31
Payable days 82.74 72.85 71.04 37.58 32.6
PER(x) 0 0 0 0 10.31
Price/Book(x) 0 0 0 0 1.43
Dividend Yield(%) 0 0 0 0 0
EV/Net Sales(x) 0.02 0.12 0.18 0.38 0.93
EV/Core EBITDA(x) 0.15 1.48 1.39 2.56 6.52
Net Sales Growth(%) 0 -10.31 -23.67 11.5 23.56
EBIT Growth(%) 0 -44.4 16.45 41.56 14.69
PAT Growth(%) 0 -53.08 4.57 71.42 26.94
EPS Growth(%) 0 -53.08 4.57 71.44 -6.68
Debt/Equity(x) 0.29 0.7 0.61 0.55 0.11
Current Ratio(x) 1.32 1.57 1.96 1.74 3.66
Quick Ratio(x) 1.28 1.24 1.38 0.89 1.93
Interest Cover(x) 20.54 6.02 5.7 7.7 14.57
Total Debt/Mcap(x) 0 0 0 0 0.08

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 23% 1% 0% 0%
Operating Profit CAGR 0% 19% 0% 0%
PAT CAGR 0% 44% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 27% NA% NA% NA%
ROE Average 20% 24% 33% 33%
ROCE Average 22% 25% 35% 35%

Company Contact Information

Amkay Products Ltd.

Bunglow No. 68, Rashmi Park, C H S Ltd Dhumal Nagar, Waliv Road Vasai (East)

IPO Lead Manager(s)

Amkay Products Ltd.

Hem Securities Ltd.

Registrar Info

Amkay Products Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!